Supplementary Figure 2 from Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Fritsch, Christine; Huang, Alan; Chatenay-Rivauday, Christian; Schnell, Christian; Reddy, Anupama; Liu, Manway; Kauffmann, Audrey; Guthy, Daniel; Erdmann, Dirk; De Pover, Alain; Furet, Pascal; Gao, Hui; Ferretti, Stephane; Wang, Youzhen; Trappe, Joerg; Brachmann, Saskia M.; Maira, Sauveur-Michel; Wilson, Christopher; Boehm, Markus; Garcia-Echeverria, Carlos; Chene, Patrick; Wiesmann, Marion; Cozens, Robert; Lehar, Joseph; Schlegel, Robert; Caravatti, Giorgio; Hofmann, Francesco; Sellers, William R.

doi:10.1158/1535-7163.22500853.v1

15357163mct130865-sup-fig_2.pdf (71.08 kB)

Supplementary Figure 2 from Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

journal contribution

posted on 2023-04-03, 14:09 authored by Christine Fritsch, Alan Huang, Christian Chatenay-Rivauday, Christian Schnell, Anupama Reddy, Manway Liu, Audrey Kauffmann, Daniel Guthy, Dirk Erdmann, Alain De Pover, Pascal Furet, Hui Gao, Stephane Ferretti, Youzhen Wang, Joerg Trappe, Saskia M. Brachmann, Sauveur-Michel Maira, Christopher Wilson, Markus Boehm, Carlos Garcia-Echeverria, Patrick Chene, Marion Wiesmann, Robert Cozens, Joseph Lehar, Robert Schlegel, Giorgio Caravatti, Francesco Hofmann, William R. Sellers

PDF - 71K, Rat1-myr-p110alpha (blue), beta (green) or delta (red) cells were treated with increasing concentrations of NVP-BYL719 for 30 minutes. Levels of S473P-Akt in cell extracts were quantified by Reverse Phase Protein Array as described in (18) and plotted as percentage of untreated control cells. The graph illustrates n=3 independent experiments. IC50s (plus/minus) SD and IC80s (plus/minus) SD of n=3 independent experiments are reported..

History

ARTICLE ABSTRACT

Somatic PIK3CA mutations are frequently found in solid tumors, raising the hypothesis that selective inhibition of PI3Kα may have robust efficacy in PIK3CA-mutant cancers while sparing patients the side-effects associated with broader inhibition of the class I phosphoinositide 3-kinase (PI3K) family. Here, we report the biologic properties of the 2-aminothiazole derivative NVP-BYL719, a selective inhibitor of PI3Kα and its most common oncogenic mutant forms. The compound selectivity combined with excellent drug-like properties translates to dose- and time-dependent inhibition of PI3Kα signaling in vivo, resulting in robust therapeutic efficacy and tolerability in PIK3CA-dependent tumors. Novel targeted therapeutics such as NVP-BYL719, designed to modulate aberrant functions elicited by cancer-specific genetic alterations upon which the disease depends, require well-defined patient stratification strategies in order to maximize their therapeutic impact and benefit for the patients. Here, we also describe the application of the Cancer Cell Line Encyclopedia as a preclinical platform to refine the patient stratification strategy for NVP-BYL719 and found that PIK3CA mutation was the foremost positive predictor of sensitivity while revealing additional positive and negative associations such as PIK3CA amplification and PTEN mutation, respectively. These patient selection determinants are being assayed in the ongoing NVP-BYL719 clinical trials. Mol Cancer Ther; 13(5); 1117–29. ©2014 AACR.

Supplementary Figure 2 from Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

History

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports